Janux Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Janux Therapeutics, Inc. carries a market capitalization of 828.78M, placing it among publicly traded companies globally. Its enterprise value stands at -70.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 828.78M |
| Enterprise Value | -70.45M |
Share Statistics
Janux Therapeutics, Inc. currently has 60.87M shares outstanding.
| Shares Outstanding | 60.87M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 62.94, and the price-to-book ratio stands at -2.30.
| PE Ratio | N/A |
| PS Ratio | 62.94 |
| PB Ratio | -2.30 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | -11.28 |
| P/OCF Ratio | -11.15 |
Enterprise Valuation
| EV / Sales | 1,093.96 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Janux Therapeutics, Inc. maintains a current ratio of 17.01, meaning it holds 17.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 17.01 |
| Quick Ratio | 16.95 |
| Debt / Equity | 2.29 |
| Debt / EBITDA | -0.14 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -11.01 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Janux Therapeutics, Inc.'s stock has declined approximately -46.55918% over the past 52 weeks. The 50-day moving average sits at 14.50, while the 200-day moving average is 18.66.
| Beta (5Y) | N/A |
| 52-Week Price Change | -46.55918% |
| 50-Day Moving Average | 14.50 |
| 200-Day Moving Average | 18.66 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Janux Therapeutics, Inc. generated 13.73M in revenue and converted that into -114.48M in net income, yielding earnings per share of -1.84. EBITDA reached -155.00M, while operating income came in at -156.98M.
| Revenue | 13.73M |
| Gross Profit | N/A |
| Operating Income | -156.98M |
| Pretax Income | -114.48M |
| Net Income | -114.48M |
| EBITDA | -155.00M |
| EBIT | -156.98M |
| Earnings Per Share (EPS) | -1.84 |
Balance Sheet
Janux Therapeutics, Inc. holds 956.39M in cash and equivalents against 21.57M in total debt, resulting in a net debt position of -51.83M. Total book value stands at -375.68M, with working capital of 943.13M providing operational flexibility.
| Cash & Cash Equivalents | 956.39M |
| Total Debt | 21.57M |
| Net Debt | -51.83M |
| Equity (Book Value) | -375.68M |
| Book Value Per Share | -6.04 |
| Working Capital | 943.13M |
Cash Flow
Janux Therapeutics, Inc. produced -77.55M in operating cash flow over the past twelve months. After subtracting -945,000.00 in capital expenditures, free cash flow totaled -78.49M - equivalent to -1.26 per share.
| Operating Cash Flow | -77.55M |
| Capital Expenditures | -945,000.00 |
| Free Cash Flow | -78.49M |
| FCF Per Share | -1.26 |
Margins
Janux Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -1,143.11 and net profit margin of -833.60 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -1,143.11 |
| Pretax Margin | -833.60 |
| Profit Margin | -833.60 |
| EBITDA Margin | -1,128.70 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.92 |
| FCF Yield | -8.86 |
Scores
Janux Therapeutics, Inc. posts an Altman Z-Score of 6.08, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.08 |